Full Press Release Details
Zymeworks Presents Additional Safety and Anti-Tumor Activity Data from the Ongoing Phase 1 Study of ZW25 at the European Society for Medical Oncology 2017 Congress (“ESMO”).
ZYME
Zymeworks Presents Additional Safety and Anti-Tumor Activity Data from the Ongoing Phase 1 Study of ZW25 at the European Society for Medical Oncology 2017 Congress (“ESMO”)
Key Takeaway: Zymeworks Presents Additional Safety and Anti-Tumor Activity Data from the Ongoing Phase 1 Study of ZW25 at the European Society for Medical Oncology 2017 Congress (“ESMO”)
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+23%
120-day peak, hindsight
Typical move
5.4%
average across 7 past catalysts
Cash runway
~35 mo
Minimal dilution risk
Lead asset
ZW49
Phase 1 · HER2-expressing Cancers